SerbinCommunications

(805) 963-0439 | Toll-Free (800) 876-6425

www.serbin.com LA / NY / UK

Cognition Studio, Inc.

CAL-101/GS-1101 and the PI3K Delta Pathway 

Prev Next
Previous

CAL-101/GS-1101 and the PI3K Delta Pathway

medical illustration of Gilead Sciences is a leader in developing innovative oral medicines targeting PI3K Delta with a focus on B-cell malignancies, including NHL and CLL. The compact design of the full handout (not shown), its concise graphics, and revealing biomedical visualizations serve as a means for the Director of PI3K Clinical Development to share these findings with investors as well as serving as an attention getting leave-behind. Initial pencil sketch with final composite in Illustrator and Photoshop.
Next medical illustration of Gilead Sciences, a leader in developing innovative oral medicines targeting PI3K Delta with a focus on B-cell malignancies, including NHL and CLL uses solutions like this to describe the PI3K pathway in a format that is easy to convey and understand while being visually compelling. Only a portion of the overall image is shown here due to space constraints. Created in Illustrator with finishing touches in Photoshop.

The PI3K delta pathway

Gilead Sciences is a leader in developing innovative oral medicines targeting PI3K Delta with a focus on B-cell malignancies, including NHL and CLL. The compact design of the full handout (not shown), its concise graphics, and revealing biomedical visualizations serve as a means for the Director of PI3K Clinical Development to share these findings with investors as well as serving as an attention getting leave-behind. Initial pencil sketch with final composite in Illustrator and Photoshop.

Keywords: Color, Design, Information Graphics, Line with Color, Advertising / Marketing, Education, Publishing, Allergy / Immunology, Biotechnology, Cell biology / Histology, Molecular Biology, Pharmacology

© 2011, Gilead Science